🟢 Connect Biopharma is trading 6.44% up in pre-market with no verified company-specific catalyst identified

Connect Biopharma is trading 6.44% up at $2.59 in pre-market, with no verified company-specific catalyst identified for August 19, 2026.

• On August 12, Connect Biopharma reported completed enrollment in Phase 2 Seabreeze STAT asthma and COPD studies; topline results are expected in September 2026.
• The broader market is only modestly higher, so the pre-market move remains unexplained rather than clearly attributable to macro sentiment.